Non-pharmacological interventions FUSE Name: FUSE Manufacturer: Novo Nordisk and GE Healthcare Current stage: Phase II Takeaway: A non-pharmacological intervention could offer fewer side effects for patients
Blai Coll, MD, Chief Medical Officer
More experienced individuals might only need 1 session per week for guidance and motivation
Analisi dell'impatto delle restrizioni Costi elevati delle terapie e copertura pubblica discontinua In Brasile, il costo mensile del semaglutide di marca raggiunge i 1,200 real brasiliani (240 dollari), circa l'80% del salario minimo, rendendolo fuori dalla portata di molti beneficiari del SUS
Weight loss is associated with a decrease in PsO severity and improved quality of life (QoL).41,42 Weight loss greater than 5% is associated with a higher rate of minimum disease activity in patients who are obese or overweight and in treatment for PsO.43,44 The Mediterranean diet, which facilitates weight loss, reduces psoriatic lesions.45 Weight loss in patients with HS leads to a notable decrease in the number of lesions and, in some cases, disease remission.46 Dysfunctional adiposity has been associated with worse indices of CVR and Dermatology Quality of Life Index (DLQI) in patients with HS.47 The decrease in fatty tissue is associated with a decrease in molecular mechanisms that characterize the systemic inflammatory state.48 Diet and exercise are the first therapeutic step but these interventions are, however, often insufficient to achieve favorable outcomes in skin diseases, good response to treatment for these conditions, and a decrease in CVR
